A novel Ca2+ channel antagonist reverses cardiac hypertrophy and pulmonary arteriolar remodeling in experimental pulmonary hypertension

European Journal of Pharmacology

Volumn 702, Issue 1-3, 2013, Pages 316-322

  Pereira, Sharlene Lopes ^a   Kummerle, Arthur Eugen ^b   Fraga, Carlos Alberto Manssour ^a   Barreiro, Eliezer Jesus ^a   Rocha, Nazareth De Novaes ^c   Ferraz, Emanuelle Baptista ^a   Nascimento, José Hamilton Matheus Do ^a   Sudo, Roberto Takashi ^a   Zapata Sudo, Gisele ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b FEDERAL RURAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

Author keywords

Hemodynamics; L type Ca2+ channel blocker; N acylhydrazone; Pulmonary arterial hypertension; Pulmonary vascular remodeling; Rat monocrotaline model

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL L TYPE; CALCIUM ION; LASSBIO 1289; N METHYL N' (THIOPHEN 3 METHYLENE)BENZO[D][1,3]DIOXOLE 5 CARBOHYDRAZIDE; UNCLASSIFIED DRUG; 1,3 BENZODIOXOLE DERIVATIVE; ACETYLCHOLINE; CALCIUM CHLORIDE; HYDRAZONE DERIVATIVE; MONOCROTALINE; N-METHYL-N'-(THIOPHEN-3-METHYLENE)BENZO(D)(1,3)DIOXOLE-5-CARBOHYDRAZIDE; PHENYLEPHRINE; VASOCONSTRICTOR AGENT; VASODILATOR AGENT; N METHYL N' (THIOPHEN 3 METHYLENE)BENZO(D)(1,3)DIOXOLE 5 CARBOHYDRAZIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL WALL THICKNESS; ARTERIOLE; ARTERY CONSTRICTION; ARTERY DIAMETER; ARTERY DILATATION; ARTICLE; CALCIUM TRANSPORT; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; ENDOTHELIAL DYSFUNCTION; EXTRACELLULAR CALCIUM; HEART RIGHT VENTRICLE PRESSURE; HEART RIGHT VENTRICLE VOLUME; HEART VENTRICLE HYPERTROPHY; IN VITRO STUDY; ISOLATED ARTERY; MALE; NONHUMAN; PRIORITY JOURNAL; PULMONARY ARTERIOLE; PULMONARY ARTERY; PULMONARY HYPERTENSION; RAT; SYSTOLIC BLOOD PRESSURE; ANIMAL; CARDIOMEGALY; CHEMICALLY INDUCED; DRUG EFFECTS; HYPERTENSION, PULMONARY; PATHOLOGY; PATHOPHYSIOLOGY; WISTAR RAT; CHEMICALLY INDUCED DISORDER;

ACETYLCHOLINE; ANIMALS; BENZODIOXOLES; CALCIUM CHANNEL BLOCKERS; CALCIUM CHLORIDE; CARDIOMEGALY; FAMILIAL PRIMARY PULMONARY HYPERTENSION; HYDRAZONES; HYPERTENSION, PULMONARY; IN VITRO TECHNIQUES; MALE; MONOCROTALINE; PHENYLEPHRINE; PULMONARY ARTERY; RATS; RATS, WISTAR; VASOCONSTRICTOR AGENTS; VASODILATOR AGENTS;

EID: 84874931620     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2013.01.050     Document Type: Article

References (35)

1. R.S. Baliga, R.J. MacAllister, and A.J. Hobbs New perspectives for the treatment of pulmonary hypertension Br. J. Pharmacol. 163 2010 125 140
2. 2+-channel blockers inhibit the action of recombinant platelet-derived growth factor in vascular smooth muscle cells Proc. Natl. Acad. Sci. 86 1989 2388 2392
3. S. Bonnet, and S.L. Archer Potassium channel diversity in the pulmonary arteries and pulmonary veins: implications for regulation of the pulmonary vasculature in health and during pulmonary hypertension Pharmacol. Ther. 115 2007 56 69
4. B.W. Christman, C.D. McPherson, J.H. Newman, G.A. King, G.R. Bernard, B.M. Groves, and J.E. Loyd An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension N. Engl. J. Med. 327 1992 70 75
5. A. Giaid Nitric oxide and endothelin-1 in pulmonary hypertension Chest 114 1998 2085 2125
6. G.E. Hardingham, S. Chawla, C.M. Johnson, and H. Bading Distinct functions of nuclear and cytoplasmic calcium in the control of gene expression Nature 385 1997 260 265
7. T. Herembert, D.L. Zhu, and P. Marche Mechanism of action of the inhibitory effect of nifedipine on the growth of cultured aortic cells from spontaneously hypertensive and normotensive rats Br. J. Pharmacol. 114 1995 1703 1709
8. D.K. Hirenallur, S.T. Haworth, J.T. Leming, J. Chang, J. Hernandez, J.B. Gordon, and N.J. Rusch Upregulation of vascular calcium channels in neonatal piglets with hypoxia-induced pulmonary hypertension Am. J. Physiol. Lung Cell Mol. Physiol. 295 2008 L915 L924
9. M. Humbert, O. Sitbon, and G. Simonneau Treatment of pulmonary arterial hypertension N. Engl. J. Med. 35 2004 1425 1436
10. M. Inoue, Y. Harada, K. Watanabe, C. Mori, and O. Tanaka The effect of nifedipine on monocrotaline-induced pulmonary hypertension in rats Acta Paediatr. Jpn. 35 1993 273 277
11. W.F. Jackson Ion channels and vascular tone Hypertension 35 2000 173 178
12. T.K. Jeffery, and J.C. Wanstall Pulmonary vascular remodeling: a target for therapeutic intervention in pulmonary hypertension Pharmacol. Ther. 92 2001 1 20
13. L. Jin, C.E. Teixeira, R.C. Webb, and R. Leite Comparison of the involvement of protein kinase C in agonist-induced contractions in mouse aorta and corpus cavernosum Eur. J. Pharmacol. 590 2008 363 368
14. H. Karaki, H. Ozaki, M. Hori, M. Mitsui-Saito, K. Amano, and K. Harada Calcium movements, distribution, and functions in smooth muscle Pharmacol. Rev. 49 1997 157 230
15. S. Kataoka, R. Alam, P.K. Dash, and F.M. Yatsu Inhibition of PDGF-mediated proliferation of vascular smooth muscle cells by calcium antagonists Stroke 28 1997 364 369
16. Y. Ko, G. Totzke, G.H. Graack, F.J. Heidgen, M.K. Meyer zu Brickwedde, R. Dusing, H. Vetter, and A. Sachinidis Action of dihydropyridine calcium antagonists on early growth response gene expression and cell growth in vascular smooth muscle cells J. Hypertension 11 1993 1171 1178
17. J.W. Koskenvuo, R. Mirsky, Y. Zhang, F.S. Angeli, S. Jahn, T. Alastalo, N.B. Schiller, A.J. Boyle, K. Chatterjee, T. De Marco, and Y. Yeghiazarians A comparison of echocardiography to invasive measurement in the evaluation of pulmonary arterial hypertension in a rat model Int. J. Cardiovasc. Imaging 26 2010 509 518
18. R.M. Lang, M. Bierig, R.B. Devereux, F.A. Flachskampf, E. Foster, P.A. Pellikka, M.H. Picard, M.J. Roman, J. Seward, J. Shanewise, S. Solomon, K.T. Spencer St, M. John Sutton, and W. Stewart Recommendations for chamber quantification Eur. J. Echocardiogr. 7 2006 79 108
19. Z.C. Li, F.Q. Zhang, J.C. Song, Q.B. Mei, and D.H. Zhao Therapeutic effects of DCDDP, a calcium channel blocker, on chronic pulmonary hypertension in rat J. Appl. Physiol. 92 2002 997 1003
20. J. Ma, and Z. Pan Retrograde activation of store-operated calcium channel Cell Calcium 33 2003 375 384
21. A. Macchia, R. Marchioli, G. Tognoni, M. Scarano, R. Marfisi, L. Tavazzi, and S. Rich Systematic review of trials using vasodilators in pulmonary arterial hypertension: why a new approach is needed Am. Heart J. 159 2010 245 257
22. + channels in pulmonary hypertension Vas. Pharmacol. 38 2002 25 33
23. E. Mawatari, M. Hongo, A. Sakai, F. Terasawa, M. Takahashi, Y. Yazaki, O. Kinoshita, and U. Ikeda Amlodipine prevents monocrotaline-induced pulmonary arterial hypertension and prolongs survival in rats independent of blood pressure lowering Clin. Exp. Pharmacol. Physiol. 34 2007 594 600
24. I. McFadzean, and A. Gibson The developing relationship between receptor-operated and store-operated calcium channels in smooth muscle Br. J. Pharmacol. 135 2002 1 13
25. J.R. Michael, T.P. Kennedy, P. Buescher, I. Farrukh, R. Lodato, P.C. Rock, J. Gottlieb, G. Gurtner, S.M. de la Monte, and G.M. Hutchins Nitrendipine attenuates the pulmonary vascular remodeling and right ventricular hypertrophy caused by intermittent hypoxia in rats Am. Rev. Respir. Dis. 133 1986 375 379
26. N.W. Morrell, S. Adnot, S.L. Archer, J. Dupuis, P.L. Jones, M.R. MacLean, I.F. McMurtry, K.R. Stenmark, P.A. Thistlethwaite, N. Weissmann, J.X. Yuan, and E.K. Weir Cellular and molecular basis of pulmonary arterial hypertension J. Am. Coll. Cardiol. 54 2009 S20 31
27. 2+ channels. Fundam. Clin. Pharmacol, 10.1111/j.1472-8206.2012.01076.x, in press
28. L.J. Rubin Primary pulmonary hypertension N. Engl. J. Med. 336 1997 111 117
29. H.S. Stanbrook, K.G. Morris, and I.F. McMurtry Prevention and reversal of hypoxic pulmonary hypertension by calcium antagonists Am. Rev. Respir. Dis. 130 1984 81 85
30. O. Stepien, J. Gogusev, D.L. Zhu, L. Iouzalen, T. Herembert, T.B. Drueke, and P. Marche Amlodipine inhibition of serum-, thrombin-, or fibroblast growth factor-induced vascular smooth-muscle cell proliferation J. Cardiovasc. Pharmacol. 31 1998 786 793
31. O. Stepien, L. Iouzalen, T. Herembert, D.L. Zhu, and P. Marche Amlodipine and vascular hypertrophy Int. J. Cardiol. 62 1997 79S 84S
32. T. Takahashi, T. Kanda, S. Imai, T. Suzuki, I. Kobayashi, and R. Nagai Amlodipine inhibits the development of right ventricular hypertrophy and medial thickening of pulmonary arteries in a rat model of pulmonary hypertension Res. Commun. Mol. Pathol. Pharmacol. 91 1996 17 32
33. S. Umar, P. Steendijk, D.L. Ypey, D.E. Atsma, E.E. van der Wall, M.J. Schalij, and A. van der Laarse Novel approaches to treat experimental pulmonary arterial hypertension: a review J. Biomed. Biotechnol. 2010 2010 1 11
34. + channel gene transcription in primary pulmonary hypertension Lancet 351 1998 726 727
35. G. Zapata-Sudo, L.B. Pontes, J.S. Da Silva, L.M. Lima, I.K. Nunes, E.J. Barreiro, and R.T. Sudo Benzenesulfonamide attenuates monocrotaline-induced pulmonary arterial hypertension in a rat model Eur. J. Pharmacol. 5;690 2012 176 182